Purespring Therapeutics

Check out Purespring’s Emerging Company Profile, published last week by BioCentury Inc. Inc!   Our CEO, Julian Hanak, and CMO, Fredrik Erlandsson, enjoyed the opportunity to sit down with Danielle Golovin, Ph.D. and discuss our novel #GeneTherapy platform, the first to selectively target the #podocyte for the treatment of chronic #KidneyDiseases and recent #pipeline progress.   Read the full company profile here to learn more: https://lnkd.in/ey9ppRWS   #Profile #Biotech #Innovation #CellAndGeneTherapy

Our Vice President of CMC, Amanda Weiss, and our Vice President of Development, Richard Truran, recently had the opportunity to participate in the Cell and Gene Therapy Summit Europe 2024 in London, UK. Hosted by Charles River Laboratories, this event aimed to bring together the leading experts, executives, and thought leaders in the Cell and #GeneTherapy space to discuss key trends and challenges. The team attended a variety of company presentations and #investor Q&As throughout the day, given by a diverse selection of subject matter experts from across the industry. Of particular interest was the closing presentation from the UK’s Medicines and Healthcare products Regulatory Agency, which highlighted important regulatory considerations in the development of gene therapy products. #Innovation #CellAndGeneTherapy #Biotech #People #KidneyDisease

On Saturday, Ambra Cappelletto, Principal Scientist at Purespring, presented new preclinical data for the first time on our novel #GeneTherapy programme, PS-002, for IgA Nephropathy (IgAN) at the American Society of Nephrology Kidney Week.   The presentation, “Podocyte Gene Therapy Enables Glomerular Complement Modulation for IgAN Treatment” outlined the results from the study, underpinning the potential of PS-002 as an important novel modality by showing that transgenes can be safely and effectively targeted to podocytes to locally modulate complement activation within the glomerulus and reduce signs of #Kidneydisease in animal models of IgAN.   The data will support progression towards the clinic as we look to translate these results into clinically meaningful benefits for patients.   To learn more, read the full press release here: https://lnkd.in/gj8ft6zb #KidneyWeek #Biotech #Conference #People #Innovation

Yesterday, Julian Hanak, CEO at Purespring, joined Amy Brown from BiotechTV to speak about our recently announced £80 million ($105 million) Series B #fundraising.   Julian delves into the development of our novel #GeneTherapy platform, the first to successfully target podocytes for the treatment of chronic kidney diseases, as well a #ClinicalDevelopment plans for our lead programme, PS-002, for the treatment of IgA nephropathy (IgAN).   For more, watch the full video: https://lnkd.in/g88xC_Dj   #Biotech #BiotechTV #KidneyDisease

This week, Head of Cell and Molecular Biology, Sarah Smith-Moore, and Research Scientist, James Matthews, are attending the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from 22-25 October in Rome, IT.   As one of the premier events in the #CellAndGeneTherapy space, #ESGCT2024 is an important platform for the global community of scientists, healthcare professionals and other stakeholders to foster collaboration, share knowledge and discuss the latest developments in the field.   If you are also attending and would like to learn more about novel #GeneTherapy platform for the treatment of chronic #KidneyDisease, please reach out to connect.   #Conference #People #Research #Innovation #Biotech #KidneyDiseases

Next week, Alice Brown, Chief Scientific Officer, Fredrik Erlandsson, Chief Medical Officer, Ambra Cappelletto, Principal Scientist, and Professor Moin Saleem, Co-Founder and Chief Scientific Advisor, will be on the ground in San Diego, CA for the American Society of Nephrology’s 2024 Annual Meeting.   Ambra will present “Podocyte Gene Therapy Enables Glomerular Complement Modulation for IgAN Treatment,” establishing the potential of our podocyte-targeting AAV #GeneTherapy, PS-002, for the treatment of IgA nephropathy (IgAN).   The presentation will take place on 26 October from 17:50-18:00 PDT in Room 1, Convention Center. If you are also attending, stop by to learn more about how our first-in-class gene therapy approach has the potential to make a real difference for patients living with chronic #KidneyDisease   To view the full abstract: https://lnkd.in/eiu98k_x   #Conference #People #Biotech #CellAndGeneTherapy

Our Senior Director of Clinical Operations, Charlotte Smerdon, attended the Evolution Summit last week, where she participated in an interactive panel on patient engagement.   The Evolution Summit is an exclusive forum that brings together leading clinical research executives and innovative solution providers. This event focussed on addressing key challenges in clinical R&D, exploring relevant market developments, and showcasing practical strategies adopted by successful pioneers in the field.   Charlotte contributed her expertise and insights on patient engagement, a critical aspect of modern clinical trials, as part of the interactive panel “From Participants to Partners: Building a Patient-Centric Trial Ecosystem”.   Her participation underscores our commitment to advancing clinical research practices and fostering innovation in patient-centric approaches.   #ClinicalResearch #PatientEngagement #EvolutionSummit #InnovationInHealthcare

We are proud to announce that we have raised £80 million ($105 million) in an oversubscribed Series B #financing led by Sofinnova Partners, alongside Forbion, Gilde Healthcare, British Patient Capital, and founding #investor Syncona Limited . This funding will be used to accelerate the development of our novel podocyte-targeting AAV #GeneTherapy platform, which has the potential to transform the lives of the 840 million people globally with kidney diseases. This includes advancing our lead programme, PS-002, which targets IgA Nephropathy (IgAN), a common, chronic kidney disease affecting young adults, towards a Phase I/II #ClinicalTrial. There are currently no therapeutic options to stop disease progression, nor a cure, and nearly one third of IgAN patients will go on to lose their kidney function within five years and require a kidney transplant or dialysis. We’re delighted to have such a high-quality syndicate of investors who have the expertise and the commitment to move this platform into clinical development, and we look forward to working with them. To learn more, read the full press release here: https://lnkd.in/eaSU6qnU #Biotech #HealthcareInnovation #KidneyDisease #SeriesB #Fundraise

Next week, Professor Moin Saleem, Purespring’s Co-Founder and Chief Scientific Advisor, will be participating in the Travere Therapeutics Rare Kidney Disease SciNet Summit from 20-21 September in Chicago, IL. Moin’s presentation will focus on #podocyte dysfunction and #GeneTherapy as part of Session 4 – Future of FSGS & MCD Diagnosis and Treatment: What’s on the Horizon on 21 September at 14:45 CDT. If you are attending the conference, please join us to learn more about the potential of our podocyte-targeting approach to treat a broad range of #KidneyDisease. #Conference #People #Biotech #Innovation

Professor Moin Saleem, our Co-Founder and Chief Scientific Advisor, has joined the Board of Trustees at Kidney Research UK (KRUK), the UK’s leading charity dedicated to finding new ways to prevent, treat and manage #KidneyDisease.   Moin and KRUK have worked together for many years, with Moin previously serving on the charity’s Research Grants Committee, as well as receiving #research funding in support of his work towards a future without kidney disease.    We look forward to continuing our work with Moin and KRUK to make a material difference to the lives of patients living with kidney disease.   #People #Innovation